收藏切换
Consideration on Research and Development of Antineoplastics in Pediatric Patients
收藏切换
Ling TANG, Jun LYU, Lin XIA, Ying GENG, Zhimin YANG*
Chinese Journal of Pharmaceuticals | 2022, 53(11) : 1664 - 1670
Less
收藏切换
Chinese Journal of Pharmaceuticals | 2022, 53(11): 1664-1670
Consideration on Research and Development of Antineoplastics in Pediatric Patients
Full
Ling TANG, Jun LYU, Lin XIA, Ying GENG, Zhimin YANG*
Affiliations
  • Center for Drug Evaluation, National Medical Products Administration, Beijing 100022
Published: 2022-11-10 doi: 10.16522/j.cnki.cjph.2022.11.023
Outline
收藏切换

Antineoplastics are one of the most active fields in new drug research and development, but there are still obvious deficiencies in the research field of pediatric antineoplastics in China. And pediatric cancer patients have an urgent need for medication. Compared with clinical trials in adults, clinical trials of pediatric population often face more challenges, exacerbating the development dilemma of pediatric drug research and development. In order to encourage the research and development of pediatric antineoplastics in China, policy support should be given to activate the research motivation of manufacturing enterprises. In the process of research and development, attention should be paid to the differences between pediatric tumors and adult tumors, the mechanism research should be strengthened, and the research and development should be determined based on the characteristics and treatment needs of pediatric cancer patients. Meanwhile, we should use adult clinical data to support the development of pediatric antineoplastics, and make full use of quantitative pharmacology and other scientific tools, so as to reduce unnecessary researches in children. We should properly grasp the opportunity to carry out studies in pediatric population, especially in children and adults with comorbidity tumors, and promote the research and development of pediatric antineoplastics as soon as possible. In addition, the special needs of children, such as rational dosage forms and long-term safety, should also be fully considered in the research and development process.

pediatric patient  /  antineoplastics  /  research and development  /  clinical trial
唐凌, 吕俊, 夏琳, 耿莹, 杨志敏. 儿童抗肿瘤药物研发思考. 中国医药工业杂志, 2022 , 53 (11) : 1664 -1670 . DOI: 10.16522/j.cnki.cjph.2022.11.023
Ling TANG, Jun LYU, Lin XIA, Ying GENG, Zhimin YANG. Consideration on Research and Development of Antineoplastics in Pediatric Patients[J]. Chinese Journal of Pharmaceuticals, 2022 , 53 (11) : 1664 -1670 . DOI: 10.16522/j.cnki.cjph.2022.11.023
Year 2022 volume 53 Issue 11
77
16
Cite this Article
BibTeX
Article Info
doi: 10.16522/j.cnki.cjph.2022.11.023
  • Receive Date:2022-07-22
  • Online Date:2026-11-12
  • Published:2022-11-10
Article Data
Affiliations
History
  • Received:2022-07-22
Affiliations
    Center for Drug Evaluation, National Medical Products Administration, Beijing 100022
References
Share
https://castjournals.cast.org.cn/joweb/zgyygy/EN/10.16522/j.cnki.cjph.2022.11.023
Share to
QR

Scan QR to access full text

Cite this article
BibTeX
Citations
表12种不同金属材料的力学参数
科
Family
属数
Number of
genus
种数
Number of
species
占总种数比例
Percentage of
total species (%)
属
Genus
种数
Number of
species
占总种数比例
Percentage of total
species (%)
鹅膏菌科Amanitaceae 2 11 5.26 鹅膏菌属 Amanita 10 4.78
小菇科 Mycenaceae 2 12 5.74 丝盖伞属 Inocybe 5 2.39
多孔菌科 Polyporaceae 8 14 6.70 蜡蘑属 Laccaria 5 2.39
红菇科 Russulaceae 3 23 11.00 小皮伞属 Marasmius 6 2.87
小菇属 Mycena 11 5.26
光柄菇属 Pluteus 5 2.39
红菇属 Russula 17 8.13
栓菌属 Trametes 5 2.39
关闭全屏
  • BibTeX
  • EndNote
  • RefWorks
  • TxT